Drug development and industrial pharmacy · 2026
Tumor microenvironment improved by nanostructured lipid carriers co-delivering paclitaxel and ubenimex to treat breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Shuai, Sheng Tao, Li Jia-Min, Zhang Bing-Feng, Peng Ruo-Bin, Yan Ping-Bo
Аннотация
OBJECTIVE: The aim of this research was to design nanostructured lipid carriers (NLCs) co-delivering paclitaxel (PTX) and ubenimex (Uben) to improve the tumor microenvironment (TME) and enhance efficacy against breast cancer.
SIGNIFICANCE: Nanostructured lipid carriers offer unique advantages for co-delivery of anti-tumor drugs, including high drug-loading capacity, controlled-release performance, and facile functionalization. This study developed a NLC co-loaded with PTX and Uben to achieve synergistic therapeutic effects on breast cancer by improving the immunosuppressive TME.
METHODS: Ubenimex was conjugated to vitamin E polyethylene glycol succinate (TPGS) via ester bonds, after which the synthetic conjugate, PTX, and lipid materials were formulated into the nanostructured lipid carrier (PTX/Uben-NLC) by the emulsified solvent evaporation-low-temperature curing method and subsequently characterized and evaluated for improved anti-tumor efficacy.
RESULTS: The prepared PTX/Uben-NLC was approximately spherical with a negative potential and a particle size of about 161 nm. The formulation demonstrated sustained drug release. Uben exhibited pH-responsive release in the weakly acidic TME and induced immune cell activation and secretion of anti-tumor cytokines (interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12)), while secretion of immunosuppressive cytokines (TGF-β and IL-10) was concurrently inhibited. PTX exerted direct anti-tumor effects on tumor cells. Consequently, the PTX/Uben-NLC alleviated TME immunosuppression and enhanced anti-breast-cancer activity.
CONCLUSION: Dual-drug-loaded NLCs alleviated TME immunosuppression to enhance synergistic anti-breast cancer therapy and provided a feasible solution for breast cancer treatment.
SIGNIFICANCE: Nanostructured lipid carriers offer unique advantages for co-delivery of anti-tumor drugs, including high drug-loading capacity, controlled-release performance, and facile functionalization. This study developed a NLC co-loaded with PTX and Uben to achieve synergistic therapeutic effects on breast cancer by improving the immunosuppressive TME.
METHODS: Ubenimex was conjugated to vitamin E polyethylene glycol succinate (TPGS) via ester bonds, after which the synthetic conjugate, PTX, and lipid materials were formulated into the nanostructured lipid carrier (PTX/Uben-NLC) by the emulsified solvent evaporation-low-temperature curing method and subsequently characterized and evaluated for improved anti-tumor efficacy.
RESULTS: The prepared PTX/Uben-NLC was approximately spherical with a negative potential and a particle size of about 161 nm. The formulation demonstrated sustained drug release. Uben exhibited pH-responsive release in the weakly acidic TME and induced immune cell activation and secretion of anti-tumor cytokines (interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12)), while secretion of immunosuppressive cytokines (TGF-β and IL-10) was concurrently inhibited. PTX exerted direct anti-tumor effects on tumor cells. Consequently, the PTX/Uben-NLC alleviated TME immunosuppression and enhanced anti-breast-cancer activity.
CONCLUSION: Dual-drug-loaded NLCs alleviated TME immunosuppression to enhance synergistic anti-breast cancer therapy and provided a feasible solution for breast cancer treatment.